ANIKNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Anika Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$20.22+0.24 (+1.20%)
Close on Oct 19, 2026
- Market cap
- $277.36M
- P/E (TTM)
- –
- Dividend yield
- –
Anika Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OEM Channel [Member] | $68.90M | $66.53M | $64.41M | $66.76M | $70.68M | $73.23M | $77.77M | – | – | – | – | – | 57.1% | -2.5% |
| Commercial Channel [Member] | $51.76M | $49.73M | $48.41M | $46.04M | $43.87M | $43.82M | $42.14M | – | – | – | – | – | 42.9% | +18.0% |
| Joint Preservation and Restoration [Member] | – | – | – | – | – | – | – | $54.64M | $56.16M | $55.27M | $54.88M | $53.93M | – | – |
| Non-Orthopedic [Member] | – | – | – | – | – | – | – | $9.05M | $9.78M | $10.38M | $9.86M | $10.08M | – | – |
| OA Pain Management [member] | – | – | – | – | – | – | – | $100.48M | $100.94M | $103.61M | $101.93M | $99.31M | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $74.11M | $72.23M | $70.06M | $73.13M | $76.27M | $78.44M | $82.45M | $93.19M | $103.44M | $116.21M | $86.91M | $122.59M | 61.4% | -2.8% |
| Europe [Member] | $25.17M | $23.08M | $22.21M | $20.55M | $19.68M | $20.64M | $19.40M | $15.63M | $16.25M | $16.22M | $17.31M | $18.01M | 20.9% | +27.9% |
| Other Location [Member] | $21.38M | $20.95M | $20.55M | $19.13M | $18.60M | $17.98M | $18.06M | $13.80M | $14.84M | $15.68M | $16.57M | $19.31M | 17.7% | +14.9% |
From the segment and revenue-disaggregation notes of Anika Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.